LISRAYA™ (brepocitinib) — Topline data
2H 2026
Non-Infectious Uveitis Ph3 Topline Data (2H 2026)Source filing
ROIV biotech catalysts & pipeline
ROIVANT SCIENCES LTD · Data as of 2026-10-25
Upcoming catalysts
IMVT-1402 — Topline data
2027
In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG.Source filing
LISRAYA™ (brepocitinib) — Topline data
1H 2027
Topline data from Phase 3 trials in non-infectious uveitisSource filing
LISRAYA™ (brepocitinib) — NDA/BLA submission
H1 2027
Priovant intends to file a supplemental New Drug Application (sNDA) for brepocitinib for the treatment of NIU in the first half of calendar year 2027.Source filing
IMVT-1402 — Topline data
2028
In calendar year 2028, topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD.Source filing
LISRAYA™ (brepocitinib) — Topline data
2028
Priovant expects the commercial launch of brepocitinib in DM by the end of September 2026 and topline data from the Phase 3 study in NIU and Phase 3 study in CS in the second half of calendar year 2026 and calendar year 2028, respectively.Source filing
IMVT-1402 — Conference presentation
2H 2026
Further updates from difficult-to-treat rheumatoid arthritis programSource filing